Collectively, our results suggest that SETD1A is a key regulator of SOX2 in BC cells and demonstrated the clinical significance of SETD1A in patients with BC that were treated with tamoxifen, indicating that SETD1A is a potential therapeutic target for the treatment of tamoxifen resistance. Here, SETD1A is linked to breast cancer.